
FDA Approves Phase 2 Trial for Cannabis-Based Autism Treatment
The U.S. Food and Drug Administration (FDA) has granted clearance for Defloria Pharmaceuticals to proceed with a Phase 2 clinical trial of its cannabis-based treatment for autism spectrum disorder (ASD). This development marks a significant step forward in exploring the potential of cannabis-derived compounds for managing autism symptoms. Defloria’s investigational new drug, DFLO-001, is specifically…